+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Fusion Inhibitor - Pipeline Insight, 2021

  • ID: 4382839
  • Clinical Trials
  • September 2021
  • Region: Global
  • 60 pages
  • DelveInsight

FEATURED COMPANIES

  • AdAlta
  • Aphios Corporation
  • Frontier Biotechnologies
  • Merck Sharp & Dohme Corp.
  • Polyphor
  • ReViral
  • MORE
This “Fusion Inhibitor - Pipeline Insight, 2021,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Fusion Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage
Fusion Inhibitor Understanding

Fusion Inhibitor: Overview


The HIV-fusion inhibitors (FIs) are peptides derived from the heptad repeat (HR)-2 region of the viral fusion protein gp41. Their mechanism of action is to prevent the formation of a critical intermediate along the virus-cell fusion pathway responsible for enacting cell-virus fusion.

"Fusion Inhibitor - Pipeline Insight, 2021" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Fusion Inhibitor pipeline landscape is provided which includes the disease overview and Fusion Inhibitor treatment guidelines. The assessment part of the report embraces, in depth Fusion Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Fusion Inhibitor collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Fusion Inhibitor R&D. The therapies under development are focused on novel approaches to treat/improve Fusion Inhibitor.

Fusion Inhibitor Emerging Drugs Chapters


This segment of the Fusion Inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Fusion Inhibitor Emerging Drugs


UB-421: United BioPharma


UB-421 is an Fc-aglycosylated, non-T cell depleting, humanized IgG1 that targets domain 1 of CD4 receptor on CD4+ T cell surface, blocking entry of HIV into the cells via a competitive binding inhibition.

MK-1654: Merck Sharp & Dohme Corp.


MK-1654 is a monoclonal antibody which acts as inhibitor of viral fusion protein and immunostimulants. It is being developed for the treatment of Respiratory syncytial virus infections and is currently in Phase III stage of development.

Fusion Inhibitor: Therapeutic Assessment


This segment of the report provides insights about the different Fusion Inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Fusion Inhibitor


There are approx. 20+ key companies which are developing the therapies for Fusion Inhibitor. The companies which have their Fusion Inhibitor drug candidates in the most advanced stage, i.e. Phase III include, United BioPharma.

Phases


This report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Fusion Inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type
The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Fusion Inhibitor: Pipeline Development Activities


The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Fusion Inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities


The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Fusion Inhibitor drugs.

Fusion Inhibitor Report Insights

  • Fusion Inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Fusion Inhibitor Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered


Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Fusion Inhibitor drugs?
  • How many Fusion Inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Fusion Inhibitor?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Fusion Inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Fusion Inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • ReViral
  • United BioPharma
  • Frontier Biotechnologies
  • Merck Sharp & Dohme Corp.
  • Aphios Corporation
  • AdAlta
  • Polyphor
  • X4 Pharmaceuticals

Key Products

  • UB-421
  • Aikening
  • MK-1654
  • APH-0202
  • AD-214
  • Balixafortide
  • X4P-001
  • X4P-002

This report will be delivered within 1-3 business days.

Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AdAlta
  • Aphios Corporation
  • Frontier Biotechnologies
  • Merck Sharp & Dohme Corp.
  • Polyphor
  • ReViral
  • MORE
Introduction

Executive Summary

Fusion Inhibitor: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
  • Comparative Analysis
UB-421: United BioPharma
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Drug Name: Company Name
  • Product Description
  • Research and Development
  • Product Development Activities
Early stage products (Phase I)
  • Comparative Analysis
AD-214: AdAlta
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical stage products
  • Comparative Analysis
X4P-002: X4 Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Fusion Inhibitor Key Companies

Fusion Inhibitor Key Products

Fusion Inhibitor- Unmet Needs

Fusion Inhibitor- Market Drivers and Barriers

Appendix

List of Tables
Table 1 Total Products for Fusion Inhibitor
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List of Figures
Figure 1 Total Products for Fusion Inhibitor
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • ReViral
  • United BioPharma
  • Frontier Biotechnologies
  • Merck Sharp & Dohme Corp.
  • Aphios Corporation
  • AdAlta
  • Polyphor
  • X4 Pharmaceuticals
Note: Product cover images may vary from those shown
Adroll
adroll